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Abstract 
Murine erythroleukemia (MEL) cells exposed to DMSO were assessed for their ability to methylate poly(A)+ RNA and accumulate 
RNA transcripts of globin and nonglobin genes (c-myc, p-a&n and MERS). Cells were pulse-labeled with t.-[methyl-3H]methionine, 
cytoplasmic RNA was isolated, selected for poly(A)+ RNA and analyzed by HPLC chromatography for methylated nucleosides. When 
MEL cells were exposed to inhibitors of RNA methylation (neplanocin A, 3-deazaneplanocin A and cycloleucine) and assessed for their 
ability to differentiate by DMSO, accumulate RNA transcripts, produce hemoglobin, methylate poly(A)+ and poly(A)- RNA and 
synthesize S-adenosylmethionine (SAM) and S-adenosylhomocysteine @AH), we observed the following: (a) MEL cells treated with 
DMSO underwent hypermethylation in poly(A)+ RNA that preferentially occurred at the S-cap structures (7-methylguanosine and 
2’Gmethylcytidine and 2’-O-methyluridine); (b) inducer-treated MEL cells exhibited a decrease in the intracellular level of SAH that led 
to a lower ratio of SAH/SAM, an event that favors methylation; and (c) treatment of MEL cells with inhibitors of RNA methylation 
suppressed methylation of poly(A)- and poly(A)+ RNA, reversed the ratio SAH/SAM seen in differentiated MEL cells and prevented 
differentiation to occur. Moreover, we observed that treatment of MEL cells with selective inhibitors of RNA methylation caused 
fragmentation of p major glohin and c-myc mRNAs, two RNA transcripts coded by developmentally regulated genes, while had no 
detectable effect on the structural integrity of poly(A)+ RNA transcripts transcribed by two housekeeping genes ( p-a&in and MERS). 
These data indicate that induction of erythroid cell differentiation of MEL cells is associated with changes in methylation of poly(A)+ 
RNA and selective differential stability of RNA transcripts, two events that might be related to each other. 
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1. Introduction 
Differentiation of murine erythroleukemia (MEL or 
Friend) cells into mature hemoglobin producing cells is 
associated with a series of morphological and biochemical 
events reviewed elsewhere [l-3]. Among these, hypometh- 
ylation of DNA was observed in terminally differentiated 
MEL cells [4], an event that has attracted considerable 
attention in recent years in developmentally regulated cel- 
lular systems [5,6]. Biochemical studies with cordycepin 
Abbreviations: DMSO, dimethyl-sulfoxide; HMBA, hexamethylene- 
bis-acetamide; UDP-4, 2-(3-ethylureido)-6-methylpyridine; SAM, S- 
adenosylmethionine; SAH, S-adenosylhomocysteine; MEL, murine ery- 
throleukemia. 
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(Y-deoxyadenosine) (an inhibitor of polyadenylation and 
methylation of RNA) and more recently with N6-methyl- 
adenosine have suggested that initiation of commitment of 
inducer-treated MEL cells to terminal erythroid maturation 
may depends on both the synthesis and posttranscriptional 
modifications of RNA, such as methylation [7-l I]. 
During posttranscriptional methylation of RNA, 
methyl-groups are transferred from SAM into specific base 
residues of RNA via RNA methyltransferases. Mammalian 
cells contain several RNA species (snRNAs, tRNAs, 
rRNAs, mRNAs) most of which are methylated at base 
residues located at unique structures like the 5’-cap in 
mRNA and the S-end of snRNAs [ 12- 151. Unfortunately, 
little is known about the biological role of RNA methyla- 
tion in cell growth and differentiation [ 16-191. 
In the present study, we extended our preliminary stud- 
ies [9,20] and explored the potential role of RNA methyla- 
tion in growth and differentiation of MEL cells. In particu- 
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lar, we investigated the following questions: (a) Do differ- 
entiating MEL cells undergo alterations in the synthesis 
and methylation of RNA? (b) If yes, do these changes 
occur simultaneously or independently during growth and 
differentiation? (c) Do poly(A)+ RNA transcripts undergo 
changes in methylation, to what extend and at which base 
residues? (d) Do the changes in RNA methylation occur 
during differentiation as a result of alterations in the 
intracellular level of SAM and SAH? (e) Are the changes 
in RNA methylation causally related to induction of MEL 
cell differentiation and production of hemoglobin? and 
finally, (f) Does inhibition of RNA methylation affect 
stability of poly(A)+ RNA transcripts? 
To approach these questions, MEL cells were treated in 
culture with and without DMSO and pulse-labeled with 
L-[methyl-‘Hlmethionine. The ability of control and differ- 
entiating cells to methylate their total cytoplasmic RNA as 
well as poly(A)+ RNAs was assessed at different times 
with the use of a modified reversed-phase HPLC chro- 
matographic method based on standard procedures [21-231. 
We analyzed [methyl-3H]-labeled poly(A)+ RNA fractions 
at the level of nucleosides and assessed the intracellular 
levels of SAM and SAH. two active intermediates in the 
methylation cycle. In a complementary series of experi- 
ments, MEL cells were exposed to both inducers of differ- 
entiation and inhibitors of RNA methylation and examined 
whether such MEL-treated cells mature, produce globin 
mRNA and hemoglobin and accumulate certain RNA tran- 
scripts and in particular those that play a critical role in 
growth and differentiation (e.g.. c-myc). Here, we wish to 
present evidence indicating that induction of hemoglobin 
synthesis and terminal erythroid maturation in MEL cells 
are associated with changes in methylation of cytoplasmic 
RNA as well as of poly(A)+ RNA. Moreover, we ob- 
served that suppression of RNA methylation led to block- 
ade of MEL cell differentiation and selective degradation 
of globin and c-myc RNA transcripts. 
2. Materials and methods 
2. I. Chemicals and biochemicals 
Dimethylsulfoxide (DMSO) was purchased by 
Mallinckrodt, (St. Louis, MO, USA). SAM, SAH, cy- 
cloleucine, HMBA, hypoxanthine, methylated and unmeth- 
ylated base and nucleoside standards were obtained from 
Sigma Chemical Co. (St. Louis, MO, USA) and were of 
the highest grade available. Neplanocin A and 3- 
deazaneplanocin A were kindly donated by Dr. Victor E. 
Marquez (National Cancer Institute, USA). UDP-4, a po- 
tent inducer of hemoglobin synthesis in MEL cells, was 
synthesized in our laboratory 1241. Analytical-grade potas- 
sium dihydrogen phosphate was purchased from Merck 
(Darmstadt, Germany). L-[methyl-3H]Methionine (80.0 
Ci/mmol) and [5,6-3H]uridine (39.6 Ci/mmol) were ob- 
tained from NEN Research Products (Boston, MA, USA) 
and [ 35 Slmethionine (1000 Ci/mmol) from Amersham 
(UK). Pl nuclease was purchased from Boehringer 
Mannheim (Mannheim, Germany), calf intestine alkaline 
phosphatase from BDH (Poole, UK) and tobacco acid 
pyrophosphatase from Sigma Chemical Co. (St. Louis, 
MO, USA). Stock solutions (1 mM) of nucleoside stan- 
dards were prepared by dissolving appropriate amounts in 
0.02 M KH,PO, solution (pH 5.6) and stored at -20°C. 
Standards of various concentrations were prepared by ap- 
propriate dilutions of the stock solutions. 
2.2. Cell cultures 
Cells employed throughout this study were MEL- 
745PC-4A a clone of MEL-745 cells obtained after sub- 
cloning and subsequent testing of clones derived for high 
degree of inducibility. All cultures were maintained in 
Dulbecco’s modified Eagles medium (DMEM) containing 
10% (v/v) fetal calf serum (Gibco, Long Island, NY) and 
antibiotics (penicillin and streptomycin 100 pg/ml). Cells 
were incubated at 37°C in a humidified atmosphere con- 
taining 5% CO2 and maintained at densities that permitted 
logarithmic growth (1 . lo5 to 1 . lo6 cells/ml). Cell via- 
bility was assessed as reported elsewhere [lo]. 
2.3. Induction and assessment of di@erentiation 
Cells were incubated with no drug and the inducing 
agent in the absence or presence of an inhibitor as indi- 
cated in the text. At certain timed-intervals during incuba- 
tion, the proportion of differentiated (hemoglobin-produc- 
ing cells) was assessed cytochemically with benzidine- 
H,O, solution [25]. The number of committed cells was 
assessed by the plasma clot clonal assay as described by 
Gusella et al. [26]. 
2.4. Pulse labeling with L-[methyl- 3H]methionine and iso- 
lation qf [methyl- -‘HJpoly(A)’ RNA 
MEL cells treated in culture under various conditions 
were removed from cultures (samples of 1.0-1.5 . 10’ 
cells) at different times and pulse-labeled in fresh methion- 
ine-free DMEM containing 10% v/v FCS for 3 h with 
L-[methyl- 3 Hlmethionine (44 pCi/ml, 80.0 Ci/mmol) in 
the presence of 20 PM adenosine, 20 PM guanosine and 
20 mM sodium formate. These agents were added in order 
to diminish the incorporation of [methyl-“HI groups into 
purine ring via the de novo biosynthesis pathway and 
increased exclusive transmethylation of RNA [27]. This 
procedure however, was not used in early experiments 
shown in Fig. 2A, where pulse-labeling of cells was 
carried out in normal DMEM without the addition of 
adenosine, guanosine and sodium formate. The latter con- 
ditions were applied in order to record kinetic changes in 
the overall methylation of cytoplasmic RNA. Cells were 
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then collected, washed with PBS solution (3 x > and pro- 
cessed for isolation of total cytoplasmic RNA [28]. Dupli- 
cate aliquots of 10 ~1 of isolated cytoplasmic RNA were 
counted for radioactivity and the extent of RNA methyla- 
tion (cpm/lOO pg RNA per3 h) was assessed. Isolated 
[methyl- 3 HI-labeled cytoplasmic RNA was then separated 
into poly(A)+ RNA fraction by passing twice throughout 
an oligo(dT)-cellulose column according to Kingston [29]. 
The purity of poly(A)+ RNA fraction was checked by 
agarose gel electrophoresis. 
2.5. Alkaline hydrolysis of [methyl- 3H]poly(A)i RNA 
Samples of [methyl-3H]-labeled poly(A)+ RNA (5 pg 
or as otherwise is indicated) were dissolved in 50 ,ul of 0.3 
M KOH and the mixture was incubated at 37°C for 19 h 
[30]. At the end of this period, 50 ~1 of 0.3 M HClO, 
solution were added and the resulting insoluble KClO, was 
removed by centrifugation (12 000 X g>. The supematant 
was collected, mixed with 50 ~1 of 0.2 M glycine buffer 
pH 9.2 containing 1.4 U of calf intestine alkaline phos- 
phatase and incubated at 37°C for 1 h [31,32]. The prod- 
ucts derived were lyophilized, dissolved in water and 
injected (20 ~1) into the HPLC column. This method 
yields nucleosides, 2’0methylated dinucleotides and in- 
tact 5’-end cap structures. 
2.6. Enzymatic hydrolysis of [methyl- 3Hlpoly(Aj’ RNA 
[Methyl-3H]-labeled poly(A)+ RNA (3 ,ug) dissolved 
in 50 ~1 solution containing 30 mM CH,COONa pH 5.3, 
2 mM ZnCl, was first digested with 2.1 U of Pl nuclease 
at 37°C for 5 h and subsequently with acid pyrophos- 
phatase (0.8 U/ml> at 37°C for 1 h in a buffer solution 
containing 20 mM Tris . HCl, pH 7.5, and 2 mM MgCl, 
[32]. After addition of 50 ~1 buffer solution (0.2 M 
glycine, pH 9.2), incubation continued for an additional 
hour in the presence of 1.4 U of alkaline phosphatase. 
Finally, the reaction mixture was lyophilized, the residue 
was dissolved in 20 ~1 of water and analyzed by HPLC. 
This method yields methylated nucleosides originating from 
the 5’-cap structure as well as from other parts of the 
mRNA molecules. 
2.7. HPLC separation of [methyl- ‘HI-labeled poly(A) ’ 
RNA digestion products 
A Varian (Sugar Land, Texas, USA) HPLC gradient 
system consisted of two Model 2510 dual-piston pumps, a 
Model 2584 high pressure solvent mixer, a Rheodyne 
Model 7125 sample injector and a Model 2550 UV-visible 
spectrophotometric detector was used. The reversed-phase 
(C18, 10 pm) Techsil 10 C,, column (25 cm X 4.6 mm 
i.d.) was purchased from HPLC Technology (Macclesfield, 
UK). Integrations and retention times were obtained using 
a Varian Model 4290 electronic integrator. Fractions of 0.5 
ml/30 s of the effluent were collected with a LKB 
(Bromma, Sweden) 2 112 Redirac fraction collector and the 
radioactivity was measured with a Packard liquid scintilla- 
tion counter. Samples (20 ~1) of hydrolytic products of 
[methyl-3H]poly(A)t RNA were loaded on the reversed- 
phase column equilibrated at 1 ml/min with 0.02 M 
KH, PO,, pH 5.6. Chromatographic runs were performed 
at ambient temperature using a 3-step linear gradient sys- 
tem of 0.02 M KH,PO,, pH 5.6 and methanol as follows: 
(a) O-2% methanol, t = 10 min; (b) 2-5% methanol, 
t = 10 min; (c) 5-35% methanol, t = 20 min. The effluent 
was monitored at 254 nm and fractions of 0.5 ml/30 s 
were collected. Each fraction was then assessed for ra- 
dioactivity. The column was re-equilibrated for at least 15 
min with the low-strength eluent between two different 
runs. Using this procedure, the retention times were repro- 
ducible. 
2.8. Detection and quantitation of SAM and SAH levels in 
cellular extracts by HPLC analysis 
Exponentially growing MEL cells (1 . lo5 cells/ml) 
were treated with one or more than one agents as indicated 
in the text. At different times, cells (2 . 106) were removed 
from cultures and labeled for 3 h at 37°C with 10 pCi/ml 
[ 35S]methionine (1000 Ci/mmol at reference date) in 
DMEM supplemented with 5% (v/v> FCS. By the end of 
this period, cells were resuspended in 1 M HClO, solution, 
sonicated for 10 s and centrifuged at 15 000 X g for 15 
min at 4°C. The supematant was collected and analyzed by 
HPLC. Samples of 20 ~1 of acid-soluble cell extracts were 
loaded on the reversed-phase column (RP-18, 5 pm, 25 
cm X 4.6 mm I.D.) and analyzed using a linear gradient 
system consisting of 0.02 M KH,PO,, pH 3.8 and 
methanol. Concentrations of methanol ranging from 0 to 
35% were used for elution within 30 min. The flow rate 
was 1 ml/min and detection of SAM and SAH was 
carried out at 254 nm. Fractions collected were counted for 
radioactivity in a liquid scintillation counter. 
2.9. Assessment of the steady-state level of RNA transcripts 
by Northern blot hybridization analysis 
Cytoplasmic RNA prepared from control and MEL cells 
treated with agents at various timed-intervals, as indicated 
in the text, was assessed for the steady-state level of RNA 
transcripts coded by pmajor globin, c-myc, p-actin and 
MER5 genes, with the use of [32P]-labeled probes, as 
previously described [10,33]. The former two genes are 
regulated and expressed developmentally, while the latter 
two are considered house-keeping genes. The probes used 
were 7.0 kb for p major globin mRNA [lo], 1.7 kb for 
c-myc mRNA [34], 350 bp for @actin mRNA [35] and 1.4 
kb for MER5 mRNA [36]. The MER5 probe was kindly 
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donated by Dr. M. Obinata of Dept. of Cell Biology, 
Tohoku University, Sendai, Japan. 
3. Results 
3.1. Growth and diflerentiation of MEL cells are associ- 
ated with alterations in synthesis and methylation of total 
cytoplasmic RNA as well as pa@(A)+ RNA 
As shown in Fig. 1 continuous exposure of cells to 
DMSO (1.5% v/v) led to a gradual accumulation of 
committed cells, an early reduction in the synthesis of 
cytoplasmic RNA and a slightly lower rate of growth. 
MEL cells grown in culture from a relatively low (5 . lo4 
cells/ml) to a high density of cells (l-2. lo6 cells/ml) 
exhibited growth phase dependent alterations in the rate of 
RNA synthesis (Fig. 1C). The rate of RNA synthesis in 
DMSO-treated cells was about 25-30% of that of control 
cells after 24 h incubation (Fig. 1C). Both control and 
DMSO-treated MEL cells exhibited changes in the state of 
methylation of total cytoplasmic RNA, as we observed 
from the results shown in Fig. 2A. The overall methylation 
increased between 12 to 36 h incubation and decreased at 
later times as cells entered the plateau phase of growth. In 
particular, DMSO-treated cells underwent hypermethyla- 
tion of RNA as compared to control untreated cells (Fig. 
2A). However, the magnitude of methylation of total cyto- 
plasmic RNA (incorporated [methyl- 3H]-groups/ 100 pg 
per 3 h) decreased at later times but remained at levels 
substantially above those of control cells. Since control 
and DMSO-treated cells continue to cycle for 72 h, these 
data indicate that growth and differentiation of MEL cells 
are associated with alterations both in synthesis and meth- 
ylation of cytoplasmic RNA. The fact that DMSO-treated 
cells exhibited decreased RNA synthesis but higher level 
of methylation indicates that RNA is methylated at a 
greater extent in differentiating cells. 
To increase the transmethylation of poly(A)+ RNA and 
to suppress any non-specific incorporation of [methyl- 
3H]-groups into purine ring due to de novo purine biosyn- 
thesis, we employed medium containing adenosine, guano- 
sine and sodiun formate as routinely used by others 
[22,27,37]. Labeling of MEL cells with L-[methyl- 
3H]methionine in methionine-free DMEM increased the 
incorporation of [methyl- ‘HI-groups into RNA fractions 
(transmethylation) by 4-fold as compared to RNA fractions 
prepared from MEL cells and labeled with t.-[methyl-3H]- 
methionine in regular DMEM. This allowed us to isolate 
more radioactive poly(A)+ RNAs and to study their pat- 
tern of methylation in both control and DMSO-treated 
MEL cells (see Fig. 2B). Induction of differentiation of 
cells by DMSO led to increased transmethylation (incorpo- 
rated [methyl-3H]-groups/ 100 pg per 3 h) of poly(A)+ 
RNAs after 36 h incubation as compared to untreated cells, 
as seen in Fig. 2B. 
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Fig. 1. Cell growth, commitment and rate of RNA synthesis in control 
and DMSO-treated cells. MEL-745PC-4A cells were incubated in DMEM 
supplemented with 10% FCS in the presence (-0-l and absence (-0-l of 
DMSO (1.5% v/v). At times indicated, cell growth was determined 
(panel Al. In parallel, cells were removed from cultures and assessed for 
commitment by the plasma clot clonal assay (panel B) according to 
Gusella et al. [26]. The rate of RNA synthesis (panel Cl was also 
measured as follows: Cells (1. 106) were removed from cultures and 
pulse-labeled with 2 @/ml [5,6-3H]uridine (spec. act. 39.6 Ci/mmol) 
at 37°C for 90 min. By the end of this period, cells were precipitated with 
an ice-cold solution of TCA (10% w/v), the insoluble material was 
collected on filters (Whatman GF/B) and washed with 5% (w/v) TCA 
solution, The filters were washed thereafter with ethanol-ether (l:l), 
air-dried and counted for radioactivity in a scintillation counter. The 
values indicated are the mean value of two separate experiments. 
3.2. Hypermethylation of poly(A)+ RNA occurs at specific 
base residues 
The results described above imply that changes in trans- 
methylation of RNA species occur during MEL cell ery- 
throid maturation. An important question then to be asked 
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Fig. 2. Kinetics of methylation of total cytoplasmic as well as poly(A)+ 
RNA in control and DMSO-treated MEL cells by pulse-labeling of cells 
with L-[methyl-‘Hlmethionine. Panel A: MEL-745PC-4A cells were incu- 
bated as indicated under Fig. 1. At time intervals indicated, samples of 
cells (3-7.10’) were removed from cultures and assayed for cytoplasmic 
RNA methylation as follows: Cells were washed out of any drug, 
resuspended in fresh normal DMEM supplemented with 10% (v/v) FCS 
(at density 8. lo6 to 1. 10’ cells/ml) and pulse-labeled with 30 wCi/ml 
of L-[methyl-3H]methionine (spec. act. 80.0 Ci/mmol) at 37°C for 3 h. 
By the end of this time, total [methyl-‘HI-cytoplasmic RNA was purified 
and counted for radioactivity in a liquid scintillation counter. Cytoplasmic 
RNA methylation was estimated by the incorporation of [methyl-“H]- 
groups per 100 pg RNA/3 h. The results presented are the average 
obtained from two separate experiments. Panel B: MEL-745PC-4A cells 
were incubated as indicated under Fig. 1. At time intervals indicated, cells 
were removed from culture and pulse-labeled in methionine-free DMEM 
with t_-[methyl-3H]-methionine (44 &i/ml, 8O.OCi/mmol) for 3 h in 
the presence of adenosine, guanosine and sodium formate. In order to 
select purified [methyl-3H]poly(A)+ RNA from isolated [methyl-‘Hlcy- 
toplasmic RNA we carried out two rounds of oligo(dT)-cellulose chro- 
matography, as described under Section 2. Poly(A)+ RNA methylation 
was estimated by the incorporation of [methyl-‘HI-groups per 100 pg of 
poly(A)+ RNA/3 h. The results presented are the average obtained from 
two separate experiments. Control C-O-) and DMSO-treated (-0-j MEL 
cells. 
was where does this methylation occur in poly(A)+ RNA? 
Two different but complementary approaches were applied 
to detect qualitative and quantitative changes in highly 
purified methylated poly(A)+ RNA derived from control 
and differentiating MEL cells. Briefly, the first approach 
involved alkaline hydrolysis of [methyl-3H]poly(A)+ RNA, 
dephosphorylation of the products and separation of the 
nucleosides derived by HPLC (Fig. 3). This approach 
yielded nucleosides, 2’-0-methylated dinucleotides and in- 
tact S-cap structures of mRNA (Fig. 4A) [30]. The second, 
involved enzymatic digestion of [methyl-“H]poly(A)+ 
RNA that also breaks down the 2’-0-methylated dinu- 
cleotides and the intact 5’-cap structures of mRNA to the 
level of nucleosides (Fig. 4B) 1321. So, the alkaline hydrol- 
ysis of [methyl-3H]-labeled poly(A)+ RNA allowed us to 
detect methylated nucleosides having 2’-OH free, while the 
enzymatic digestion methylated nucleosides derived from 
the S-cap structures and 2’-0-methylated dinucleotides as 
well as other methylated derivatives from elsewhere of the 
poly(A)+ RNA. Furthermore, the enzymatic hydrolysis of 
RNA allowed detection of methylated nucleosides that 
otherwise were unstable in alkaline conditions (e.g. 7- 
h P 
lo 20 30 40 d 
r I B 
L 
20 30 40 M 
Elution time ( min ) 
Fig. 3. HPLC elution pattern of known methylated and non-methylated 
nucleosides and bases. Panel A: A mixture of l-2 nmol of each substance 
indicated in a total volume of 20 ~1 was injected on a reversed-phase 
column (Techsil 10 C ,s, 25 cm X 4.6 mm) and chromatographed using a 
gradient system of two solvents as described under Section 2. Panels B 
and C: Cytoplasmic [methyl-sH]poly(A)- RNA was isolated from control 
MEL cells and hydrolyzed by alkali treatment as described under Section 
2 for poly(A)+ RNA. The RNA hydrolysis products mixed (panel C) or 
not (panel B) with known internal standards and analyzed by the HPLC 
method (shown in panel A). The peak of absorbance of added known 
methylated and unmethylated nucleosides is indicated by the arrows. 5 
pg of RNA was hydrolyzed for each run. Abbreviations: C, cytidine; 
mC,, 5-methylcytosine; U, uridine; m’I, 7-methylinosine; m5C, 5-meth- 
ylcytidine; C,, 2’Gmethylcytidine; m7G, 7-methylguanosine; G, guano- 
sine; U,, 2’.O-methyluridine; m’ I, 1-methylinosine; m’ G, 1 -methyl- 
guanosine; m*G, N,-methylguanosine; A, adenosine; A,, 2’-O-methyl- 
adenosine; m6A, N6-methyladenosine and rn: A, N’, N6-dimethyladeno- 
sine. 
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Fig. 4. HPLC analysis products derived from alkaline hydrolysis and/or 
enzymatic digestion of [methyl-‘H]poly(A)+ RNA. Samples of 3 pg of 
[methyl-3H]poly(A)+ RNA prepared from DMSO-induced MEL cells 
(60 h of incubation) were hydrolyzed by alkali (panel A) or digested with 
Pl nuclease first and acid pyrophosphatase thereafter (panel B) to yield 
nucleotides. The nucleotides were then converted to nucleosides by 
alkaline phosphatase and analyzed by HPLC as described in Fig. 3. The 
arrows indicate the retention time of known nucleosides and bases at 254 
nm absorbance length. 
methylguanosine, 1-methylinosine, 1-methyladenosine, 3- 
methylcytidine) [30]. 
3.4. Inhibitors of RNA methylation afSected cell growth 
and prevented erythroid differentiation of MEL cells in- 
duced by various agents 
Detailed HPLC analysis of [methyl- 3H]poly(A)+ RNA To demonstrate whether the changes seen in RNA 
prepared from control and DMSO-treated MEL cells by methylation in differentiating MEL cells are causally re- 
using the HPLC system described in Fig. 3, is shown in lated to induction of erythroid maturation, we employed an 
Fig. 5. The left panels indicate the alkaline hydrolysis additional experimental approach. We exposed cells sepa- 
profile of methylated nucleosides derived from [methyl- 
‘H]poly(A)” RNA partially contaminated with poly(A)- 
rately to neplanocin A, 3-deazaneplanocin A and cy- 
RNA (one round purification via oligo(dT)-cellulose col- 
cloleucine, three selective inhibitors of RNA methylation 
139-411 and asked if such treated MEL cells continue to 
umn). The right panels indicate the time dependent accu- differentiate by inducers, produce globin and non-globin 
mulation of alkaline hydrolysis products derived from 
highly purified [methyl- 3H]poly(A)+ RNA from control 
mRNAs and synthesize hemoglobin. These agents are 
and differentiating MEL cells. It is interesting to note that 
claimed to have selective action on methylation reactions 
as judged from the work published elsewhere [42-501. 
treatment of cells with DMSO led to gradual accumulation 
of S-cap structures (fractions 7-101, as confirmed by the 
Treatment of cells with each of RNA methylation inhibitor 
enzymatic hydrolysis with acid pyrophosphatase, Pl nucle- 
at concentrations known to block RNA methylation 
ase and alkaline phosphatase (Fig. 4B). m7G, C,, U,, and 
(neplanocin A 1 . 10m6 M, 3-deazaneplanocin A 1 . 10e5 
another as yet unidentified methylated nucleoside (fraction 
M and cycloleucine 4. lo-* M) [39-41,511, in the pres- 
59) were detected in 5’-cap-structures (Fig. 4). These 
ence of DMSO decreased cell growth (Fig. 7A) whereas 
changes were pronounced after 60 h treatment with DMSO. 
the viability of MEL cells was affected to a lesser degree, 
as expected (Fig. 7B) [5 1 I. However, co-treatment of MEL 
The only internal methylated nucleoside detected in 
poly(A)+ RNAs from DMSO-treated cells was m’G (frac- 
cells with each inhibitor and inducer prevented erythroid 
differentiation to occur. No substantial amount of 
tion 61) as confirmed by the alkaline hydrolysis and the 
parallel enzymatic digestion of poly(A)+ RNA (Fig. 4). 
hemoglobin was produced (Fig. 70. The fact that the 
These results are in agreement with the hypermethylation 
inhibitors of RNA methylation prevented MEL cell differ- 
entiation promoted by HMBA, UDP-4 and hypoxanthine, 
of poly(A)+ RNA seen in DMSO-treated MEL cells (Fig. 
2B). 
3.3. Alterations in the level of SAM and SAH during 
growth and differentiation of MEL cells 
Changes in the extent and pattern of methylation of 
cytoplasmic as well as of poly(A)+ RNA seen during 
MEL cell differentiation can result from analogous alter- 
ations in the level of SAM and SAH, since the ratio 
SAH/SAM regulates the rate of methylation of macro- 
molecules within the cells [38]. By using an HPLC system 
similar to that described before (Fig. 6D), we observed that 
control and DMSO-treated MEL cells pulse-labeled with 
[ 35 Slmethionine underwent changes in the intracellular 
level of SAM and SAH (Fig. 6A and B). After an early 
increase, the level of SAM in control cells gradually 
dropped to a lower level. The level of SAH increased after 
12 h of incubation and remained constant thereafter in 
these cells. Overall the ratio SAH/SAM increased in 
control cells after an early transient reduction (Fig. 6C). In 
contrast, DMSO-treated MEL cells exhibited a gradual 
reduction in the level of SAM just after an early increase. 
Similarly, the level of SAH markedly decreased in such 
inducer-treated cells (Fig. 6A and B). These changes in the 
level of both SAM and SAH kept the ratio SAH/SAM at 
a level significantly lower than that of control cells (Fig. 
60. 
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three other inducers in addition to DMSO (Table 1), caused a pronounced inhibition of methylation of poly(A)- 
suggests that RNA methylation may be part of the central and poly(A)+ RNA, both 3-deazaneplanocin A and cy- 
process leading to differentiation and not an isolated event cloleucine exerted a more selective inhibitory effect on 
specific to an inducer. Finally, all the inhibitors of RNA methylation of poly(A)+ RNA rather than of poly(A)- 
methylation prevented erythroid differentiation of MEL RNA (Table 2). This suggests that the inhibition effect of 
cells by sodium butyrate, another potent inducing agent latter agents on methylation of poly(A)+ RNA is more or 
(data not shown). less specific. 
3.5. Treatment of MEL cells with RNA methylation in- 
hibitors reduced methylation of poly(A)’ and poly(A)+ 
RNA and increased the ratio SAH / SAM 
To verify that treatment of MEL cells with each in- 
hibitor of RNA methylation in the absence and presence of 
inducer DMSO prevents RNA methylation at concentra- 
tions used, we measured methylated RNA fractions in 
control and DMSO-treated cells. While neplanocin A 
As illustrated in Table 2, exposure of MEL cells to 
either neplanocin A or 3-deazaneplanocin A for even one 
hour led to rapid accumulation of SAH, whose level was 
hardly detectable prior treatment in both control and 
DMSO-treated cells (data not shown). Longer exposure 
(24 h) of DMSO-treated cells to neplanocin A and 3- 
deazaneplanocin A led to accumulation of SAH (Table 2) 
prior to commitment. In contrast to neplanocin A and 
3-deazaneplanocin A treatment, exposure of cells to cy- 
cloleucine led to rapid depletion of SAM, without affecting 
I. Alkaline hydrolysis of Imethyl-3Hl-polyA + 
RNA samples purified after o tin& mind 
of chromatography on oligoldlj-cellulose 
0 20 40 60 80 
6 B.-caps DMSO 48hr 
1 l+G 
II. Alkaline hydrolysis of [methyl-SHI-polyA+ 
RNA samples purified after am 
of chromatography on oligoktT)cellulose 
6 Y-caps 
! 1 4 m'G 
: 
0 20 40 60 80 
0 0 W.(\* -- 20 40 60 80 
Fraction number Fraction number 
Fig. 5. HPLC analysis products derived from alkaline hydrolysis of [methyl-‘H]poly(A)+ RNA prepared from control and DMSO-treated MEL cells. 
MEL-745PC-4A cells were incubated in the absence or presence of DMSO (1.5% v/v). At times indicated, [methyl-“H]poly(A)+ RNA was purified after 
one (left panels) or two (right panels) rounds of chromatographic separation of identical [methyl-‘Hlcytoplasmic RNA samples (see Section 2) and 
hydrolyzed (5 pg) by alkali treatment. The products were co-chromatographed with known methylated nucleosides on the HPLC system as shown in Fig. 
3. Fractions of 0.5 ml/30 s were collected and counted for radioactivity. 
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Fig. 6. Alterations in the intracellular levels of SAM and SAH in control 
and DMSO-treated MEL cells. MEL-745PC-4A cells were incubated in 
the presence (-0-j or absence (-a-) of DMSO (1.5% v/v). At time 
intervals indicated, cells (2. 106) were removed from cultures, pulse- 
labeled with 10 pCi/ml [35S]methionine (spec. act. 1000 Ci/mmol) at 
37°C for 3 h. Acid soluble cellular extracts were prepared and analyzed 
by HPLC, as shown in the right panel (D). (Panel D: A mixture consisted 
of 1-3 nmol of each of the compounds indicated above (20 ~1 total 
volume) was injected on a reversed-phase column (RF-l& 5 pm, 25 
cmX4.6 mm) and chromatographed as described under Section 2). The 
level of SAM and SAH at each time point was estimated by the amount 
of radioactivity corresponding to SAM (panel A) or SAH (panel B) 
derived from each sample. The values of ratio SAH/SAM were also 
estimated and are shown in panel C. Abbreviations: SAM, S-adenosyl- 
methionine, SAH, S-adenosylhomocysteine, Ado, adenosine, N6-SAH, 
S-N6-methyladenosylhomocysteine and N6-mAdo, N6-methyladenosine. 
N6-SAH was prepared using known methods [11,75,76]. 
the level of SAH as expected. Overall, the reversion in the 
ratio SAH/SAM was less dramatic in DMSO-treated cells 
exposed to cycloleucine for 24 h than to neplanocin A and 
3-deazaneplanocin A (Table 2). These data indicate that 
the blockade of MEL cell differentiation caused by these 
agents is associated with alterations in RNA methylation 
and changes in the intracellular level of SAM and SAH. 
3.6. The inhibitors of RNA methylation caused differential 
stability of house- (@actin, MERS) and non-house-keeping 
genes ( p mojo r globin, c-myc) 
To investigate whether inhibition of RNA methylation 
that leads to blockade of MEL cell differentiation also 
affects accumulation of RNA transcripts of various genes, 
some of which are house-keeping ( /?-actin, MERS) and 
others are developmentally regulated ( /3 major globin, c- 
myc), we carried out the following study: we exposed cells 
to each inhibitor in the presence and absence of the 
inducer DMSO for various times and then assessed the 
steady-state level of intact and degraded poly(A)+ RNA 
transcripts. This study has shown the following: (a) treat- 
ment of MEL cells with DMSO alone led to cytoplasmic 
accumulation of p major globin mRNA (Fig. 8A)., while 
caused marginal effect on RNA transcripts coded by two 
housekeeping genes ( p-actin, MERS) (Fig. 8C and D). 
However, exposure of cells to each inhibitor of RNA 
methylation in the presence or absence of inducer altered 
the pattern of accumulation of c-myc RNA transcripts and 
caused fragmentation of fimajor mRNA, an event previ- 
ously observed with N6-methyladenosine, another in- 
hibitor of MEL cell differentiation [lo]. In addition, expo- 
sure of MEL cells separately with each methylation in- 
hibitor alone led to relatively high levels of pmajor mRNA 
although fragmented, as compared to control untreated 
cells (Fig. 8A). Fragmentation was also observed in RNA 
transcripts coded by c-myc (Fig. 8B), a growth-gene in- 
volved in the regulation of commitment to maturation in 
MEL cells [52,53]; (b) Northern blot hybridization analysis 
for p-actin and MERS transcripts, indicated that the 
z so 
‘i; - 
‘g aeso 
e- 
gy40 z 3” 
c” 20 
d 0 
0 24 48 72 % 
Time (hrs) 
1 
Fig. 7. Effects of neplanocin A, 3-deazaneplanocin A and cycloleucine on 
cell growth, viability and DMSO-induced differentiation of MEL cells. 
Exponentially growing MEL-745PC-4A cells were treated in culture with 
the following additions: none f-0-1, DMSO (1.5% v/v) (-0-I. DMSO 
(1.5% v/v)+neplanocin A (1.10e6 M) (-A-), DMSO (1.5% v/v)+3- 
deazaneplanocin A (1. 10m5 M) (-m-l and DMSO (1.5% v/v)+ 
cycloleucine (4. 10m2 M) (-A -1. Cell growth (panel A) and viability 
(panel B) were determined 48 h later, while the proportion of differenti- 
ated cells (panel C) was scored after 96 h as described elsewhere [lo]. 
Each time point represents the mean value of two separate experiments. 
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Table 1 
Inhibition of MEL cell differentiation by neplanocin A, 3-deazaneplanocin A and cycloleucine in the presence of different inducing agents 
Treatment Concn. (M) Cell growth Viability Benzidine-positive 
(% of control) (%o) cells (%) 
none _ 100 98.8 <I 
DMSO 0.210 103 99.2 69.6 
DMSO + neplanocin A 0.210 + 1 1o-6 50.6 97.0 1.9 
DMSO + 3-deazaneplanocin A 0.210 + 1 10-s 39.3 97.0 1.8 
DMSO + cycloleucine 0.210 + 4 10-Z 52.8 95.4 15.9 
HMBA 5 10-j 34.8 96.8 76.4 
HMBA + neplanocin A 5 lo-1+ 1’ 10-e 29.2 89.2 9.5 
HMBA + 3-deazaneplanocin A 5~10-~+1~1o-s 24.7 87.6 10.2 
HMBA + cycloleucine 5.10-‘+4.10-2 23.6 86.7 25.0 
UDP-4 2.5 1O-4 53.9 98.1 74.0 
UDP-4 + neplanocin A 2.5 1O-4 + 1 1O-6 47.2 97.6 6.0 
UDP-4 + 3-deazaneplanocin A 2.5. 10-j + 1 lo-’ 39.3 97.0 4.1 
UDP-4 + cycloleucine 2.5. IO-J +4. IO-* 32.5 97.5 14.0 
Hypoxanthine 5.5 10-j 74.1 98.4 40.7 
Hypoxanthine + neplanocin A 5.5 10-s + 1 lo-b 38.2 98.0 2.9 
Hypoxanthine + 3-deazaneplanocin A 5.5 10-j + 1’ 10-s 37.1 98.3 2.8 
Hypoxanthine + cycloleucine 5.5’ 10-‘+4’10-* 31.5 97.4 12.1 
Exponentially growing MEL-745PC-4A cells were incubated with and without an inducing agent (DMSO, HMBA, UDP-4, hypoxanthine) at its optimum 
inducing concentration as well as with the inducer in the presence of neplanocin A, or 3-deazaneplanocin A and/or cycloleucine at concentrations 
indicated. Cell growth and viability were determined after 48 h whereas the proportion of differentiating cells after 96 h of incubation. Each value indicated 
is the mean value of two separate experiments. 
steady-state level of both these RNA transcripts remained 
constant since no substantial degradation occurred (Fig. 8C 
and D). In addition, considering that the cytoplasmic RNA 
we prepared was intact as shown by the ethidium bromide 
staining pattern of the RNA samples (Fig. 8E), we con- 
clude that inhibition of RNA methylation in MEL cells 
selectively affects stability of RNA transcripts coded by 
two developmentally regulated genes ( p major globin and 
c-myc) that play a critical role in MEL cell differentiation. 
4. Discussion 
The central mechanism(s) which govern the initiation of 
commitment of MEL cells to terminal erythroid maturation 
Table 2 
Effect of neplanocin A, 3-deazaneplanocin A and cycloleucine on RNA methylation of MEL cells grown in the presence and absence of DMSO 
Treatment Concn. (M) Methylation of RNA a (spec. act. of [methyl-3HlRNA) Ratio 
poly(A)- RNA 
kpm/ 100 wg RNA) 
poly(A)+ RNA 
kpm/ 100 pg RNA) 
SAH/SAM 
A. Without DMSO 
None 
Neplanocin A 
3-deazaneplanocin A 
Cycloleucine 
B. With DMSO 
DMSO 
DMSO + Neplanocin A 
DMSO + 
3-deazaneplanocin A 
DMSO + Cycloleucine 
_ 354761 (100) 127783 (100) 0.023 b 
1 10-h 124834 (35.2) 18099 (14.2) 0.854 b 
1’ 1o-5 302340 (85.2) 27931 (21.9) 1.185 b 
4 lo-? 438080 (123.5) 70956 (55.5) 0.230 b 
0.210 503551(141.9) 133071(104.1) 0.045 c 
0.210 + 1 10-6 210042 (59.2) 18750 (14.7) 0.940 c 
0.210 + 
1 10-s 524732 (147.9) 16823 (13.2) 1.023 ’ 
0.210 + 4 lo-* 649592 (183.1) 8482 (6.6) 0.097 c 
For the measurement of RNA methylation MEL cells were incubated in culture with and without DMSO (1.5% v/v) as well as separately with neplanocin 
A, 3-deazaneplanocin A and/or cycloleucine at concentrations indicated in the presence and absence of DMSO. After 24 h incubation, cells were 
pulse-labeled with L-[methyl-sH]methionine as described in Section 2. By the end of this time, total cytoplasmic [methyl-sH]RNA was isolated and 
separated into poly(A)- and poly(A)+ fractions by oligddT)-cellulose chromatography. The specific activity of each RNA species was measured with the 
use of a liquid scintillation counter. The ratio SAH/SAM was calculated as reported elsewhere [74]. 
a Numbers in parentheses indicate the level of methylation as compared to that of control cells. 
b.c These numbers indicate the level of SAH/SAM ratio after: b 1 h and ’ after 24 h incubation of each methylation inhibitor indicated, as reported under 
Section 2. 
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are not as yet fully understood. Earlier studies suggested 
that initiation of commitment of MEL cells depends on the 
synthesis of new RNA and proteins [l-3,54]. It has also 
been shown that MEL cell differentiation is associated 
with hypomethylation of DNA [4], an event that may not 
be considered as a crucial initiative event, but still quite 
important for gene activation [5,6]. Earlier studies with 
cordycepin that synchronizes commitment of MEL cells 
[7] and blocks polyadenylation and methylation of RNA 
[S] indicated that induction of commitment depends on a 
methionine-sensitive event [ 101. In this study, we extended 
earlier studies from this laboratory [9,20] and explored the 
role of RNA methylation in induction of MEL cell differ- 
entiation. 
I- 48hr--, I 72hr.1 
1 2 3 4 5 6 7 8 9 101112 
That poly(A)’ RNA methylation occurs in MEL cells 
like in other eukaryotic cells is not surprising since meth- 
ylated bases have been detected in different mRNAs [12], 
as well as in other RNA species (tRNAs, rRNAs, snI2NAs) 
[ 13- 151. What is interesting in this case, however, is that 
the extent of methylation of cytoplasmic RNA increased in 
differentiating MEL cells while the overall RNA synthesis 
markedly decreased. Kinetically, cells entering the plateau 
phase of growth after 60-72 h incubation exhibited a 
reduction in the rate of RNA methylation, while DMSO- 
treated cells continued to methylate their RNA at a higher 
extent. This finding suggests that hypermethylation of 
cytoplasmic RNA may be a part of the differentiation 
process rather than a cell-cycle related event. The increase 
r 48hrI ,--- 72hr -1 
1 2 3 4 56 7 8 9101112 1-e 
1 
Fragments of 
pmajorglobin 
mRNA 
C 
r 48hr--, ,- 72hr.-1 r 
48hr ---, ,--- 72hr -, 
1 2 3 4 5 6 7 8 9 101112 1 2 3 4 5 6 7 8 9 101112 
28s - 28s - 
c-myc - 
18s - 18S, 
MER-5 - 
,--48hr,,----72hr---, 
12345678910111 
285 - 
18s - 
E 
Fig. 8. Assessment of the effect of neplanocin A, 3-deazaneplanocin A and cycloleucine on cytoplasmic accumulation of p maJo’ globin, MER.5, c-myc and 
mouse p-actin RNA transcripts in control and DMSO-treated cells (Northern blot analysis). Samples of 10 pg total cytoplasmic RNA prepared from 
MEL-745PC-4A cells exposed to either each inhibitor of RNA methylation only or to both DMSO and an inhibitor as indicated below and for different 
times shown in the panels were electrophoretically separated on 1% agarose gel, transferred onto a nylon (Hybond-N, Amersham) membrane and 
hybridized at 65°C with 32P-labeled DNA fragments coding either for p maJar globin mRNA (7.0 kb) [lo], or for mouse cytoplasmic p-actin mRNA (350 
bp) [35], or for c-myc mRNA (1.7 kb) 1341, or for MERS mRNA (1.4 kb) [36], according to a method described by Church and Gilbert [33]. The filter was 
then washed at 65°C and autoradiographed using Kodak XAR-5 film. The autoradiograms obtained are shown above. Panel E shows the corresponding 
ethidium bromide staining patterns of electrophoresed RNA samples (the positions of 28s and 18s rRNAs are indicated). MEL cells were treated with the 
following additions: Lane 1, none; Lanes 2 and 6, DMSO (1.5% v/v); Lanes 3 and 7, DMSO (1.5% v/v) + neplanocin A (1 10m6 M); Lanes 4 and 8, 
DMSO (1.5% v/v)+ 3-deazaneplanocin A (1 1O-5 M); Lanes 5 and 9, DMSO (1.5% v/v) +cycloleucine (4. lo-* M); Lane 10, neplanocin A 
(1 10m6 MI; Lane 11, 3-deazaneplanocin A (1 . lo-’ M) and Lane 12, cycloleucine (4. lo-’ M). 
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in methylation of RNA was observed several hours after 
the reduction of RNA synthesis, but not simultaneously. 
HPLC analysis of [methyl- 3H]poly(A)+ RNA revealed 
methylated constituents at 5’-cap structure (m7G, C,, U,) 
and hardly detectable levels of m6A (Figs. 4 and 5). It must 
be noted that l-methylguanosine (m’G) was detected in 
poly(A)+ RNA from DMSO-treated cells for the first time. 
The gradual accumulation of [methyl- 3H]-labeled 5’-cap 
structure constituents in DMSO-treated cells (Fig. 5) indi- 
cates that mRNAs are relatively hypermethylated at the 
5’-cap structure during differentiation as well as at other 
base residues. At some sites, methylation occurs on the 
base residue while in others at 2’-OH position of ribose. 
Unfortunately, the analytical methods employed here did 
not permit us to demonstrate whether transmethylation of 
RNA at internal base residues occurs randomly or at 
discrete regions of RNA molecules. 
Alterations in RNA methylation observed during 
DMSO-induced MEL cell differentiation can be attributed 
either to changes in the intracellular level of SAM and 
SAH or to alterations in the activity of RNA methyltrans- 
ferases. As shown in Fig. 6A, the level of SAM decreased 
in both control and differentiating MEL cells by different 
rates following an early increase. In contrast, the level of 
SAH remarkably increased in control cells, while dramati- 
cally decreased in differentiating cells from the first hours 
of incubation with DMSO. Overall, a lower ratio of 
SAH/SAM observed in differentiated cells (Fig. 6C). 
These changes in the ratio SAH/SAM appear to affect the 
degree of RNA methylation, since RNA methyltransferases 
may no longer be inhibited by SAH [38]. Technical difli- 
culties in achieving detectable level of RNA methylation 
in vitro did not allow us to assess endogenous RNA 
methyltransferase activity in control and DMSO-treated 
cells (data not shown). 
Although the data presented thus far indicate that MEL 
cell differentiation is associated with both qualitative and 
quantitative changes in poly(A)+ RNA methylation at 
specific sites, the precise role of these changes in matura- 
tion of MEL cells remains elusive. Hypermethylation of 
course could increase hydrophobicity of RNA and may 
facilitate RNA transport from nucleus into cytoplasm as 
reported by Camper et al. [37]. Alternatively, hypermeth- 
ylation may affect the tertiary structure and conformation 
of RNA in a way that renders it capable to interact with 
trans-acting proteins like in other cases [55-621. Further- 
more, changes in methylation of RNA at several sites may 
affect its stability, an event that occurs during MEL cell 
differentiation [63-651 and is developmentally regulated 
[65]. A study showing an increase in methylation of 5.8 S 
rRNA in normal tissues versus neoplastic cells (HeLa and 
Novikoff hepatoma) has been reported [ 181. Similarly, the 
role of RNA methylation was also examined in L5 my- 
oblast cell differentiation [ 191. 
To further support the notion that there may be a causal 
relationship between methylation of RNA and specific 
events of MEL cell differentiation, we employed a reverse 
but complementary approach mentioned above. Knowing 
that RNA methylation can be inhibited by agents like 
neplanocin A, 3-deazaneplanocin A and cycloleucine which 
have been already used in many cellular systems as spe- 
cific inhibitors of methylation reactions [39-511, it was 
reasonable to investigate whether selective inhibition of 
methylation of nuclear RNA and most importantly of 
cytoplasmic poly(A)+ RNA leads to: (a) alterations in 
SAH/SAM ratio, (b) changes in the steady-state accumu- 
lation and stability of RNA transcripts coded by various 
genes (MERS, /3-actin, c-myc and pmajor globin), and (c) 
blockade of maturation. We are aware that although the 
methylation inhibitors employed in this study are specific 
inhibitors of active methylation cycle, one can argue that 
they can affect methylation of other macromolecules in 
addition to RNA. We reason that their effect on DNA 
methylation must be negligible, since this process is al- 
ready suppressed in differentiating MEL cells [4]. Further- 
more, if DNA methylation was a rate-limiting step in MEL 
cell differentiation, then we would expect to see induction 
of differentiation rather than inhibition since evidence 
exists to indicate that MEL cell differentiation is associ- 
ated with DNA hypomethylation [4]. However, the rela- 
tively high steady-state level of pmajor globin mRNA in 
cells exposed exclusively to methylation inhibitors and fail 
to undergo terminal maturation may be due to DNA 
hypomethylation as seen by treatments of MEL cells with 
5-aza-cytidine and 5-aza-2’-deoxy-cytidine [66]. DNA hy- 
pomethylation can occur at 5’-end upstream sequences 
adjacent or distant from the globin genes that contain 
transcription cis-control elements in a way seen in LCR 
region (HS region) of the globin genes [67-691. The 
findings that co-treatment of MEL cells with DMSO and 
each of the inhibitors of RNA methylation blocked induc- 
tion of erythroid maturation, suppressed the steady-state 
level accumulation of pmajor globin and c-myc RNA 
transcripts and decreased their stability while had no de- 
tectable effect on p-actin and MERS RNAs, suggest that 
RNA methylation and RNA stability may be related to 
each other in MEL cell differentiation. 
The findings presented here are also in agreement with 
previous studies showing that N6-methyladenosine [ 10,ll I, 
3-deazaadenosine [70], cordycepin [7], 5’-methylthioa- 
denosine [7 1,721 and 5’-S-isobutylthioadenosine [71], which 
modulate the methylation cycle [8,11,73] inhibit initiation 
of MEL cell differentiation. Methylation of RNA may be a 
critical event in induction of erythroid differentiation of 
MEL cells. Moreover, knowing that commitment of MEL 
cells depends on the synthesis of new RNA and proteins as 
well as on methylation and differential stability of poly(A)+ 
RNAs, it is reasonable to assume that inhibition of RNA 
methylation may block initiation of differentiation by af- 
fecting stability of critical RNA transcripts. Of course, this 
is an interesting working hypothesis pending further inves- 
tigation and approval. 
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